vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Target Price of $55.83

vTv Therapeutics Inc. (NASDAQ:VTVT) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $55.83.

A number of equities research analysts have commented on the company. Wall Street Zen downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. HC Wainwright lowered their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and issued a $57.00 price target on shares of vTv Therapeutics in a report on Wednesday, October 14th. Finally, Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd.

vTv Therapeutics Price Performance

VTVT opened at $23.55 on Friday. The business has a 50 day simple moving average of $29.89 and a 200-day simple moving average of $33.42. The stock has a market capitalization of $92.79 million, a P/E ratio of -22.22 and a beta of 0.28. vTv Therapeutics has a 12 month low of $22.45 and a 12 month high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Research analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. lifted its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,360 shares of the biotechnology company’s stock after acquiring an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 at the end of the most recent quarter. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.